Beijing Beilu Pharmaceutical (300016.SZ) has obtained the "Drug Registration Certificate" for Compound Polyethylene Glycol Electrolyte Powder (III).

Beijing Beilu Pharmaceutical (300016.SZ) announced that the company recently received approval from the National Medical Products Administration of China for the issuance of the Compound Polyethylene Glycol Electrolyte Powder (III) "Drug Registration Certificate". The Compound Polyethylene Glycol Electrolyte Powder (III) was approved as a Class 4 chemical drug, equivalent to passing the evaluation of generic drug quality and efficacy consistency. This further enriches the company's product pipeline in the field of digestive system diseases and enhances the company's market competitiveness in the treatment of digestive system diseases.